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Abstract
Sequencing cancer genomes may enable tailoring of therapeutics to the underlying biological 
abnormalities driving a particular patient’s tumor. However, sequencing-based strategies rely 
heavily on representative sampling of tumors. To understand the subclonal structure of primary 
breast cancer, we applied whole genome and targeted sequencing to multiple samples from each of 
50 patients’ tumors (total 303). The extent of subclonal diversification varied among cases and 
followed spatial patterns. No strict temporal order was evident, with point mutations and 
rearrangements affecting the most common breast cancer genes, including PIK3CA, TP53, PTEN, 
BRCA2 and MYC, occurring early in some tumors and late in others. In 13/50 cancers, potentially 
targetable mutations were subclonal. Landmarks of disease progression, such as resisting 
chemotherapy and acquiring invasive or metastatic potential, arose within detectable subclones of 
antecedent lesions. These findings highlight the importance of including analyses of subclonal 
structure and tumor evolution in clinical trials of primary breast cancer.
Introduction
Driver mutations occur in single cells, and are associated with subsequent clonal expansions. 
Consequently, a given patient’s breast tumor comprises a complex patchwork of genetically 
related, competing clones1-3. Genome sequencing has enabled analysis of clonal evolution in 
breast cancer through sequencing of primary tumor and metastasis pairs in a few cases4,5, 
sequencing of single cells2,6 and xenograft models7 as well as deep sequencing for subclonal 
mutations1,3. These studies have revealed that subclonal evolution is found in breast cancer, 
albeit based on relatively small sample sizes.
Most breast cancers are localized at first presentation and managed with curative intent 
using surgery often combined with radiotherapy and systemic therapies. Therapies targeted 
against the estrogen and HER2 receptors improve survival and benefit may extend to cases 
where the targetable alteration is subclonal8,9. Therapies directed against a wider range of 
biological targets are currently in early phase trials but heterogeneity could complicate study 
design and confound analysis10,11. The optimal therapy may be directed against mutations 
shared by all cells in a cancer but later, subclonal mutations may be important if they enable 
subclones to resist treatment or confer metastatic capacity. In colon, pancreatic and 
hematological cancers, preferred temporal orders of somatic mutation accumulation may 
predominate12-15, but whether this exists in breast cancer has not been evaluated. In renal, 
pancreatic, colon and prostate tumors, geographical stratification of clonal structure is 
common, with subclones containing driver mutations expanding locally16-21. Whether early 
breast cancers show similar patterns is unknown.
Results
Multiregion sequencing of breast cancer
To determine the patterns of spatial evolution in primary breast cancer, we undertook 
sequencing of multiregion samples from 50 invasive cancers (27 ER+/HER2−, 3 
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ER+HER2+, and 20 triple negative (ER−PgR−HER2−); Supplementary Table 1). We 
sequenced the cancers in two cohorts. In cohort 1, we performed prospective, systematic 
needle biopsy sampling of 12 primary, treatment-naïve, surgically excised cancers (Fig. 1a–
b). In cohort 2, we studied multiple treatment-naïve needle biopsy or tissue block samples 
from 38 cancers (Fig. 1a and c). All but 2 cases in cohort 2 underwent neo-adjuvant 
chemotherapy with 10 demonstrating a complete pathological response and 26 having 
histopathologically confirmed residual disease. For 18 of these 26 cancers, we sequenced 
samples from both pre-treatment and post-treatment residual, invasive disease. For 290 
samples from the 50 cancers, we sequenced to high coverage (mean = 166x) (Supplementary 
Table 2) 360 known cancer genes, chosen from review of published literature22-24 and 
including over 40 genes recurrently mutated in breast cancer3,25-30 (Supplementary Table 3). 
For 13 of these cancers we sequenced selected tumor samples (n = 29) and a matched 
constitutional DNA sample in each case to whole genome level with an average depth of 40-
fold (Supplementary Table 2).
We identified driver mutations as recurrent mutations in oncogenes or truncating mutations 
and recurrent missense substitutions in tumor suppressor genes3,14,25,27,28,30,31 (details of 
driver mutation annotation in Online Methods). Copy number analysis focused on the 5 
most frequent arm level copy number changes32 and 12 frequently amplified genes in breast 
cancer33,34 (Supplementary Table 3b).
False positive and false negative mutation calls in multi-sample studies can lead to the 
appearance of subclonal heterogeneity that is in fact artifactual. To validate our pipeline, we 
repeated the targeted capture experiment using independent libraries for 38 needle biopsy 
samples from 5 cancers. Positive predictive values and, critically, negative predictive values 
were on average > 99%, confirming our ability to call both the presence and the absence of 
individual mutations across multiple samples from a single cancer (Supplementary Table 4). 
From whole genome sequencing data, we successfully verified 2,217 of 2,235 (99%) 
substitutions and 18 of 19 (95%) indels (Supplementary Table 4). We confirmed 1,567 of 
1,778 (88%) structural variants using PCR or breakpoint-associated copy number changes 
(Supplementary Table 4). We achieved 97% concordance between copy number 
amplifications called by targeted gene sequencing and by multiplex-ligation dependent 
probe amplification (Supplementary Table 4). We validated phylogenetic trees reconstructed 
from whole genome data (Supplementary Fig. 1, Supplementary Table 5) by targeted deep 
sequencing of mutations on each proposed branch. Cohort 2 contained fresh frozen and 
FFPE samples with no systematic differences in mutation calls (Supplementary Fig. 2).
Geographical patterns of subclonal growth
To assess the spatial distribution of subclones for 12 cancers, we sliced the tumour in half 
immediately after surgical resection and obtained six needle biopsy samples from the cut 
face of each half (Fig. 1b). We performed targeted gene sequencing from 8 biopsies from 
each primary tumor and an associated lymph node metastasis in 3 cases (Fig. 1a). We 
evaluated the remaining four biopsies from each primary tumour by histopathology to 
confirm the presence of invasive cancer and assess Ki67 levels (Supplementary Table 1).
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Eight of twelve tumors demonstrated statistically significant spatial heterogeneity of point 
mutations (q < 0.05) and a further 2 samples displayed heterogeneity of copy number 
changes alone (Fig. 2a–d, Supplementary Table 6). Layering mutational data onto the spatial 
arrangement of biopsies demonstrated that local, geographically constrained expansion is the 
predominant pattern of heterogeneity with 10 out of 12 cancers having at least one mutation 
confined to 1–3 adjacent regions.
Localized confinement of subclones was not always the case. In four cancers, we found 
evidence of admixture of clones (Fig. 2d, Supplementary Fig. 3–4). The subclonal mutations 
often had low, but variably distributed, allele fractions in the samples where they were 
detected, a pattern suggestive of extensive intermingling of subclones across wide 
geographical ranges. This pattern was only common amongst larger tumors (4 of 5 tumors > 
3cm). Similar findings have been observed in follicular lymphoma and colorectal 
cancer15,17.
In all 12 cancers, we identified at least one clonal somatic driver mutation or copy number 
event shared by all samples. In 4 cancers, we identified subclonal driver mutations, 
including recurrent TP53 missense mutations, MYC amplification, a canonical mutation in 
PIK3CA and a nonsense mutation in BRCA2. In these 4 examples, the subclonal driver 
mutation was absent from 5–7 of the 8 samples sequenced despite a collective coverage of 
around 1,000-fold. In 7 of 12 cases, some mutations were subclonal in the tumor as a whole 
but could be erroneously characterized as clonal if only a single biopsy were sequenced 
(Supplementary Fig. 3).
Subclonal growth in multifocal cancer
For 4 cancers, we sequenced samples from more than one focus (2–5) of a multifocal cancer. 
In each case, separate foci of disease were clonally related (Fig. 3). Within individual foci, 
we found that many private mutations had high variant allele fractions, indicating that 
during the growth of each focus, complete ‘clonal sweeps’ had occurred in which a clone 
completely replaced all other tumor cells in that focus. In 3 of 4 cases, mutations private to a 
disease focus included known driver events: BRCA2 and CDKN2A inactivation (Fig. 3a), 
PTEN point mutation (Fig. 3c-d) and CDK6 amplification (Fig. 3e).
The complex intermixing of minor subclones seen in some unifocal tumors also existed 
within and between multiple foci of disease (Fig. 3a–b, colored arrow-heads). By definition, 
lesions in multifocal breast cancer are separated by apparently normal breast tissue. 
Therefore, the fact that these distinct foci are clonally related shows that subclones in these 
developing tumors are capable of transiting considerable distances through normal breast 
tissue by the lymphatic, ductal or microcirculatory systems as has been demonstrated in 
metastatic prostate cancers35.
PD9694, a multifocal ER+HER2− cancer with two macroscopic foci and several microscopic 
foci of invasive disease occurring within a large region of scattered DCIS, embodies a 
remarkable example of subclonal dissemination (Fig. 3c–d). Two distinct PTEN driver 
mutations appeared in the different regions – these mutations had evolved in parallel during 
the tumor’s development (Fig. 3c) and were confined to disease with invasive potential (Fig. 
Yates et al. Page 4
Nat Med. Author manuscript; available in PMC 2016 January 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
3d). Critically, we detected one or the other of the PTEN mutations in discontiguous areas of 
microinvasive disease within predominant DCIS (Fig. 3c). The most plausible explanation 
for this is that the two PTEN-null subclones disseminated intraductally within the DCIS, 
setting up several new, discrete foci of invasion.
Subclonal driver mutations in multifocal cancers were not restricted to point mutations, with 
one sample showing a high-level CDK6 amplification in one focus absent from the other 
(Fig. 3e). The CDK6-amplified focus showed only a partial response to neoadjuvant 
chemotherapy, whereas the other focus underwent a complete pathological response.
Variable extent of subclonal heterogeneity in breast cancer
Across the 50 cancers in cohorts 1 and 2, we assessed intratumoral heterogeneity in the 
targeted gene screen, taking into account fluctuations in normal cell contamination and 
sequence coverage. For 23 cancers, no significant difference in point mutations 
(Supplementary Table 7) existed across the different tumor subregions (Fig. 1a, 
Supplementary Table 6), although in 4 of these cases, there was heterogeneity in copy 
number changes. For three cancers, we detected profound heterogeneity, exemplified by 
private mutations in most of the samples (PD14753, PD9850, PD12334). Most cancers, 
however, had intermediate levels of intratumoral heterogeneity.
We created an index of heterogeneity based on discordance of mutation frequencies 
averaged across all possible pairs of samples from each cancer, after adjusting for normal 
cell contamination and differences in coverage (Online Methods). Our data indicated no 
correlation between the level of heterogeneity and histology, ER status, grade, intratumoral 
lymphocyte infiltration or Ki67 score of the tumor (Supplementary Fig. 5b–h). 
Heterogeneity in Ki67 scores across samples did not correlate with our index of genomic 
heterogeneity (Supplementary Fig. 5i). We detected a trend towards a greater degree of 
heterogeneity with increasing age at diagnosis (p = 0.05, F-test) and larger tumor size (p = 
0.005, F-test) amongst triple negative cancers. Notably, response to neoadjuvant 
chemotherapy, typically anthracycline-based regimens with or without a taxane, did not 
correlate with the extent of intratumoral heterogeneity amongst pre-treatment samples in this 
cohort, albeit with limited sample size (p = 0.2, F-test) (Supplementary Fig. 5e).
To test if genetic heterogeneity inferred from targeted capture data matches genome-wide 
distribution, we performed multiregion whole genome sequencing on 10 cancers (Fig. 4). 
For each, the thousands of somatic base substitutions allowed us to reconstruct phylogenetic 
trees and to determine the subclonal composition of each sampled region (Fig. 4, 
Supplementary Fig. 1). As for the targeted capture analysis, the extent of subclonal 
diversification varied markedly between tumors (Fig. 4a–b). We found good correlation 
between the branching time implied from whole genome data and the heterogeneity score 
determined from targeted capture analysis of samples from the same cancer (Fig. 4d).
Resistant subclones may be unmasked by chemotherapy
For 18 cancers, we sequenced DNA from both diagnostic biopsies and residual, invasive 
disease after neoadjuvant chemotherapy. In 6 cases, mutations appeared to be subclonal 
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(present in < 100% of tumor cells) in both pre- and post-chemotherapy samples indicating 
that some subclones persist despite treatment (Fig. 4a–c, black outlined branches: PD9768, 
PD9770, PD9771, PD9777, PD14748, PD14757). In 5 cancers, we identified a subclone in 
the post-chemotherapy residual tumor mass not evident in pre-chemotherapy samples (Fig. 
4a–c, red outlined branches: PD9768, PD9769, PD9770, PD9771, PD9777). Within these 
treatment-resistant subclones, potential driver mutations included amplifications of CDK6 
(PD9770), FGFR2 and MYC (PD9777) and a deletion within RUNX1 (PD9769).
Variants found only in post-chemotherapy samples could either represent mutations 
acquired during chemotherapy or mutations present in pre-existing subclones that were not 
sampled before therapy. For three cases, we had detailed phylogenies from samples before 
and after chemotherapy (PD9770, PD9777 and PD9771). In the latter 2, the branching point 
of the post-treatment subclone (Fig. 4a; red-filled circles) predated the branching point 
inferred from pre-treatment samples only (black cross). Post-treatment (purple outline) and 
pre-treatment subclone branches (purple outline) were of similar lengths, suggesting a 
similar molecular age. Furthermore, similarity in mutational signature profiles 
(Supplementary Fig. 6a) in the pre- and post-treatment branches suggests minimal 
contribution from chemotherapy-induced mutagenesis. Clones detected only in residual 
tumor mass after neoadjuvant chemotherapy are therefore likely to represent subclones in 
which most of the mutations are already present prior to treatment, a conclusion also reached 
by evolutionary simulations of breast cancers before and after chemotherapy36.
Metastases can derive from subclones detectable in the primary tumor
For two cases, we studied whole genomes from primary tumor biopsies and a metastatic 
deposit. In the first case (PD9771), the lung metastasis and prechemotherapy biopsies all 
arose from a subclone that contained over 800 base substitutions (yellow branch, Fig. 4a–b) 
and 43 structural variants. Notably, the residual disease sample, which also represents a 
chemotherapy-resistant population of cells, arose from a separate subclone (purple branch). 
In the second cancer (PD9849), we found that an axillary lymph node metastasis arose from 
a defined subclonal lineage detected within the primary tumor (Fig. 4a–b, Supplementary 
Fig. 1, PD9849: cluster 3), and not from the trunk of the phylogenetic tree.
This finding has clinical relevance – if metastatic disease arose from a very early branch of 
the phylogenetic tree, before all subclonal diversification within the primary tumor, treating 
actionable mutations that were subclonal in the primary tumor would not help prevent 
disease relapse. Although needing confirmation in larger studies, our results corroborate 
FISH-based studies of aneuploidy in metastatic breast cancer, which have also suggested 
that metastases arise from subclones of the primary cancer37.
Subclonal driver mutations and parallel evolution
Across the cohort, the majority of driver point mutations and copy number changes were 
present in all lesions sequenced, suggesting they occurred before emergence of the cancer’s 
most recent common ancestor (Fig. 5a). Although numbers of subclonal driver mutations are 
too low to reach definitive conclusions about individual genes, and phylogenetic 
reconstruction gives only relative, not absolute, timing of driver mutations, it is clear that 
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many of the common breast cancer genes can be mutated either early or late in disease. 
Driver mutations in TP53, PIK3CA, PTEN, BRCA2, CDKN2A were subclonal in some 
tumors in our study and fully clonal in others. Likewise, amplifications of MYC, CDK6 and 
FGFR1 sometimes occurred late in evolution. In 13 of 50 cancers, subclonal mutations 
affected genes that are potential targets of systemic therapies in clinical use or in 
development (Supplementary Fig. 6b).
We found four cancers with parallel evolution of driver mutations, including the case with 
convergent PTEN mutations discussed above (Fig. 4a–b, Supplementary Fig. 6c: PD9694, 
PD9777, PD9769, PD9850). In a triple negative cancer (PD9777), we found three small, 
amplified episomal circles containing FGFR2, each present subclonally within the cancer 
and at variable proportions across the different samples, at least two of which must have 
arisen independently (Fig. 5b). In an ER+/HER2− cancer (PD9850), three separate subclonal 
lineages each carried different TP53 driver mutations (including a recurrent, silent mutation 
affecting TP53 splicing, Fig. 5c, Supplementary Fig. 6d). In a triple negative cancer 
(PD9769), we found distinct focal genomic rearrangements specifically deleting coding 
exons of RUNX1 in two subclonal branches (Fig. 5d, Supplementary Fig. 6e). Three of the 
four examples of parallel evolution represent the second hit in a tumor suppressor gene, with 
the first hit located on the trunk of the phylogenetic tree (Supplementary Fig. 6c–e).
Ongoing structural variation in subclonal diversification
We assessed the relative activity of mutational processes over time for the 10 multi-region 
whole genomes (Fig. 6b–d). The proportion of structural variants that are subclonal broadly 
matched the proportion of subclonal substitutions (r = 0.94), although in some cancers, such 
as PD9777, late structural variants are the predominant driver of subclonal diversification 
(Fig. 6b–e).
Similar to point mutational signatures (Supplementary Note, Supplementary Fig. 6b), 
rearrangement processes active early in tumor evolution tended to continue later in disease 
(Fig. 6c–d). For some cancers, tandem duplications dominated the structural variant 
landscape, sometimes numbering hundreds, and these continued to accumulate late in 
disease (Fig. 6d). Complex chromosomal events are a frequent feature being present in 7 of 
10 cancers, and include 4 breakage-fusion-bridge cycles, a chromothripsis event followed by 
amplification and complex, amplification-associated rearrangements (Fig. 6c). In 5 tumors, 
complex events occurred both early and late in tumorigenesis and in some cases resulted in 
subclonal amplification of oncogenes (Fig. 6e, Supplementary Table 8), suggesting that 
catastrophic events can remodel the genome late in evolution and provide the phenotypic 
diversity upon which selection may operate.
Discussion
Most breast cancers are diagnosed at an early stage and are considered curable. Once 
established, distant metastatic disease is incurable, meaning that prevention of metastasis 
represents our best opportunity to improve breast cancer cure rates. We find that metastases 
can derive from subclones in the primary cancer, emphasizing the importance of 
understanding the patterns, extent and nature of subclonal diversification in primary tumors.
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We find variable degrees of genomic heterogeneity across breast cancers, notwithstanding 
the fact that targeted gene sequencing may underestimate subclones. This contrasts with the 
profound heterogeneity seen almost universally in clear cell renal cell carcinoma (RCC), 
where subclonal diversification occurs early after VHL mutation18,19. In non-small cell lung 
cancer, subclonal heterogeneity is less marked38, and minimal in early (stage IA-IIIA) 
tumors31. Kidney cancers are often large (> 10cm) when diagnosed, whereas breast and lung 
cancers are typically smaller. Indeed, we find a correlation between tumor size and degree of 
heterogeneity in triple negative breast cancer. The direction of causality is unclear – it may 
be that tumors with profound heterogeneity grow to larger sizes, or it may be that beyond a 
certain size, complete clonal sweeps, where an especially fit clone expands to replace all 
other subclones in the tumor, become unlikely. In colon cancer, there is evidence that the 
latter can explain observed patterns of subclonal heterogeneity17.
Transcriptome and histological studies have shown that breast cancer comprises many 
subtypes39-42, with distinct biological, prognostic and therapeutic implications. We find that 
subclonal heterogeneity can be present in all major immunohistological subgroups of breast 
cancer, but our ‘all-comers’ study design prevents us from drawing definitive conclusions 
about any particular subtype. Heterogeneity may explain cases of borderline ER and HER2 
positivity43,8, where survival benefits from anti-endocrine therapies extend to cancers with 
nuclear ER staining in as few as 1% of tumor cells8,44. FISH-based studies have found that 
heterogeneity of copy number changes predicts response to neoadjuvant chemotherapy36, 
something we did not observe. Resolving this discrepancy will require studies focusing on 
specific molecular subtypes of breast cancer with larger sample sizes, potentially in the 
setting of clinical trials of neoadjuvant therapies.
Understanding subclonality is fundamental to improving cancer care but will require 
prospective integration of genomics studies into clinical trials45. Important issues such as 
which subclones give rise to metastasis and the potential clinical benefits of treating 
subclonal actionable mutations can be addressed, provided sample size, sample acquisition 
and sample analysis are carefully planned. Drug development is increasingly ‘rational’, 
based around improved understanding of each tumor’s individual biology: drug testing 
should follow this lead, incorporating the biology of cancer evolution into trial design and 
evaluation.
Online Methods
Sample acquisition
In this exploratory study, we analyzed a total of 303 multi-region tumor samples from 50 
subjects’ breast cancers and a matched normal sample, derived from blood (n = 49) or 
adjacent normal breast tissue (n = 1). Cohort 1 consists of 98 samples from 12 cancers 
(average of 8.2 samples per cancer, range = 8–10). Cohort 2 comprises 205 samples from 38 
cancers (average of 5.4 per cancer, range = 2–21) (Supplementary table 1). All subjects are 
female and in cohort 1 and 2 the average age at diagnosis is 67 years (range = 44-90 years) 
and 49 years (range = 29-67 years) respectively (Supplementary table 1). Sample collection 
and management complies with local institutional review board approvals and details are 
provided in the Supplementary Note. Samples in cohort 1 represent those from 12 patients 
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undergoing primary surgery, who provided informed consent to participate in a prospective 
study. They encompass 12 geographically pre-determined tissue samples (15-20 mg) 
obtained using a 14G Tru-cut needle from fresh surgical specimens following the map in 
Figure 1b. In cohort 2 we studied de-identified residual tissue samples collected during 
routine clinical care. Samples in cohort 1 are derived from fresh needle biopsy specimens 
(n= 98) while those in cohort 2 are from a combination of diagnostic tumor biopsies (n = 95) 
and surgical specimen tissue blocks (n = 110) fixed in FFPE (n = 104) or fresh frozen at 
acquisition (n = 101) (Supplementary Table 1). Experienced local pathologists performed 
histopathological review of all primary tumors including IHC for ER and PgR Allred scores, 
and HER2 status with FISH confirmation for HER2 IHC scores of 2+ or 3+ (Supplementary 
Table 1). Pathologists assessed intra-tumoral and stromal lymphocytes according to the 
criteria previously described46 and Ki67 staining as described in the Supplementary Note 
and presented in Supplementary Table 1). Sample size was chosen to ensure that genes 
mutated in > 10% of tumors were sampled on average 5 times in the cohort.
DNA extraction
We performed DNA extraction from serial thick sections cut from tumor tissue samples. 
Pathologist guided macro-dissection ensured tumor cell enrichment in cases where the 
invasive tumor content was estimated to be less than 50% of cells. For two patients with 
multi-focal disease (PD9193, PD9694) we used histopathologically guided needle dissection 
of FFPE samples. We isolated tumor DNA from fresh or fresh frozen tissues using the 
DNeasy® Blood and Tissue Kit and from FFPE tissues using QIAamp® DNA FFPE Tissue 
Kit or Argylla Technologies® DNA nanoPurify kit. We used QIAGEN’s® QIAamp® DNA 
Blood Maxi Kit, QIAamp® DNA Mini Kit or DNeasy® Blood and Tissue Kit to isolate 
DNA from whole blood. In all cases we followed protocols according to the manufacturer’s 
recommendations.
Genomic sequencing
We created targeted capture pull-down (average insert size 150bp) and genome-wide, shot-
gun (insert size 300-600bp) libraries from native DNA using previously described 
workflows1,14,47 (details in Supplementary Note) and generated paired-end sequence data 
(75bp and 100bp respectively) using Illumina HiSeq® machines. The sequence data, aligned 
to the human reference genome (NCBI build37) using BWA48 is deposited in the European 
Genome-Phenome Archive (https://www.ebi.ac.uk/ega/ at the EBI) with accession numbers 
EGAD00001000965 and EGAD00001000898. Within the custom targeted capture 
experiment we sequenced 290 tumor samples from 50 subjects’ cancers to a mean target 
coverage of 160x with 63% of exonic regions achieving >= 100-fold coverage 
(Supplementary Table 2). We sequenced to whole genome level 29 tumor and 13 matched 
normal samples with average sequence coverage of 40 and 31 fold respectively 
(Supplementary Table 2). We used both sequencing approaches for 16 tumor samples.
We used 2 in-house cancer gene panels (CGP, versions v1 and v2) designed to pull down a 
selection of genes (454 and 360 genes respectively) that are known, or suspected to play a 
role in cancer (Supplementary Table 3). The panel targets genes from the Cancer Gene 
Census (COSMIC)24, genes recurrently amplified or over-expressed in cancer22,23 and 
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candidate cancer genes such as kinases from the MAP Kinase signaling pathway. All genes 
in CGP v2 are also in CGP v1 - only genes present in both CGP v1 and v2 are presented in 
these analyses. We performed custom RNA bait design following manufacturers’ guidelines 
(SureSelect®, Agilent®, UK) to create designs of approximately 2Mbp in size. The data 
from 63 and 240 tumor samples is derived form CGP v1 and v2 respectively Supplementary 
Table 1.
Somatic mutation calling
Comprehensive lists of all somatic substitutions, small insertions and deletions (indels) 
structural variants including variant allele frequencies from both whole genome and targeted 
capture analysis are available for download at ftp://ftp.sanger.ac.uk/pub/cancer/YatesEtAl/. 
All high confidence mutation calls within the scope of the cancer gene panel are presented in 
Supplementary Table 7. Coding substitution and indel calls and structural variants with 
potential oncogenic effects, identified in whole genome data, are summarized in 
Supplementary Table 8. Mutation calling algorithms used in the analysis are freely available 
at https://github.com/cancerit/ and are described in the Supplementary Note.
Validation approaches
When exploring heterogeneity determining when a mutation is absent is at least as important 
as determining when the mutation is present. To address this we performed validation using 
custom pull-down and sequencing of mutations identified in any sample (Illumina HiSeq® 
or MiSeq®) in all related samples from the same cancer. We enriched the validation 
experiment with mutations that appeared to be heterogeneous (from the branches of 
phylogenetic trees) or that defied the consensus tree. Across the 39 whole genome tumour 
samples we selected in excess of 2,000 somatic substitution locations for validation and 
created a 473kbp custom capture probe design using Agilent® Technologies freely available 
online software ‘Sure Select Design Wizard’ using high-stringency repeat masking, a tiling 
density of 2X and balanced boosting. We created DNA capture (paired-end, average insert 
size 150bp) libraries using native DNA where resources permitted, or if necessary using 
whole-genome amplification (WGA). We sequenced multiplexed libraries to an average 
depth of 265X using the Illumina MiSeq® platform. When a variant is called present in the 
tumor sample and absent in the matched normal sample in both discovery and validation 
experiments for one or more related sample we report it as validated somatic (see 
Supplementary Note for details of validation calls). Using these criteria 99% (2,217 out of 
2,235) of substitutions validated somatic (Supplementary Table 4). The remaining calls are 
not detectable in any relevant sample’s validation data (false positive, n=10) or detected in 
the matched normal at validation (germline, n=7). We confirmed absence of 1,301 out of 
1,683 (77%) of mutations. Overall concordance between the 2 experiments (true positives 
and true negatives/ all validation calls) was 90% (5,003 out of 5,527). The overall level of 
concordance for the targeted capture experiment is higher, with consistency between 189 out 
of 191 validation and discovery calls (99% concordance), likely reflecting the higher 
coverage in this experiment (Supplementary Table 4, Supplementary Note).
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Variant annotation
To identify likely driver events we first identified from the literature the genes that are most 
likely to contribute to breast cancer oncogenesis. For each individual mutation that fell in 
one of these 45 high confidence breast cancer genes we assigned a likely oncogenic status as 
follows: Presumed oncogenic – Mutations that meet any of the following criteria:
i. Canonical oncogenic mutations in recurrent hotspots
ii. Recurrent mutations in a known oncogene: >= 2 confirmed non-synonymous or in 
frame deletion, somatic mutations have previously been confirmed at this locus in 
COSMIC
iii. Likely damaging events in a known tumor suppressor: Truncating, frameshift, 
essential splice variant or within a mutation hotspot (>= 2 somatic mutations) or 
Synonymous mutation in a known recurrent splice site hotspot49
Possible oncogenic – Previously unreported variant in a high confidence breast cancer gene 
that occurs within 3 amino acids of >= 2 confirmed somatic mutations or truncating events 
in ‘medium confidence’ tumor suppressors (defined as known tumour suppressor role in 
cancers other than breast cancer). All other non-synonymous mutations are assigned a status 
of unknown relevance. Using these criteria the 260 mutations identified across the dataset 
are annotated as follows: 87 oncogenic, 8 possible oncogenic, 124 of unknown oncogenicity 
and 41 nononcogenic (synonymous) (Supplementary Table 3).
Copy number analysis
Likely driver copy number changes are reported for individual samples within the targeted 
gene capture experiment in Supplementary Table 7, and for whole genome samples in 
Supplementary Table 8. Segmental copy number information was derived for each of the 29 
tumor samples for which we had whole genome NGS data using the ASCAT algorithm 
(allele-specific copy number analysis) of tumors as previously described32. The algorithm 
simultaneously determines and utilizes aberrant cell fraction and ploidy estimates to 
determine allele specific copy number from NGS data. A segment is considered amplified if 
it is present at more than twice the estimated average ploidy across the whole genome. 
Homozygous deletions are identified as segments where total copy number equals zero 
(subclonal homozygous deletions if copy number is less than 1). Visual inspection of copy 
number transitions and reconstructed, associated rearrangement breakpoints are used to 
validate driver copy number events as described in the Supplementary Note.
Within the targeted capture experiment we evaluated copy number using libraries from the 
ASCAT algorithm and used LogR and BAF values to identify five of the most frequent arm 
level copy number changes in breast cancer – 16p and 17p loss and 1q, 8q, 16p gain32 and 
amplification of 12 genes frequently identified as amplified in breast cancers (FGFR1, MYC, 
CCND1, CCND3, CCNE1, CDK4, CDK6, IGF1R, ZNF217, AURKA, EGFR and 
ERBB2)33,34. Details are provided in the Supplementary Note alongside the targeted capture 
copy number validation approach that employed multiplex ligation dependent probe 
amplification (Supplementary Table 4).
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Statistical and informatics approaches
We performed statistical analysis and produced graphics using R version 3.0.1: A language 
and environment for statistical computing (R Foundation for Statistical Computing, Vienna, 
Austria. URL http://www.R-project.org/). The stars() function generated coxcomb plots. 
Other packages used include RColorBrewer, xlxs , lme4, mgcv, as well as packages from 
bioconductor50. All hypothesis tests performed in the manuscript are 2-sided where 
appropriate.
Measuring heterogeneity in targeted capture data
(i) Estimating variant allele frequencies and confidence intervals—In a 
sequencing experiment with finite coverage it is likely to completely miss mutations present 
at low variant allele frequency (VAF). Our point estimate of the VAF is
where x is the observed number of reads reporting the variant and n is the coverage. This is 
the maximum likelihood estimated under a simple binomial sampling model,
It is, however, also possible to observe x reads if the true VAF is greater than the ML 
estimate. To decide what is the maximal allele frequency compatible with our data, we 
defined a one-sided 95% confidence interval CI to be that VAF beyond which the 
probability to observe x or less reads is smaller than 5%,
where F denotes the cumulative density function of the binomial distribution.
(ii) Testing for presence or absence of mutations—For the purposes of determining 
if an individual mutation is present or absent, as displayed in the driver mutation heatmap 
(Figure 5) we determined the presence of each mutation in a dichotomous fashion in each 
sample. A mutation is considered to be: (i) Present if found at positive variant allele 
frequency (VAF > 0); (ii) Indeterminate in cases with no detectable VAF = 0, but 95% 
confidence intervals spanning CI > 5% allele frequency, as the absence of such mutations 
could not be ruled out with sufficient certainty; (iii) Absent if undetectable (VAF = 0) and 
the 95% confidence interval CI < 5%. Only in such cases are mutations reported as 
heterogeneous.
(iii) Measuring Heterogeneity—In addition to sampling fluctuations, the observed VAF 
is confounded by the tumor cell fraction T. Any comparison of VAF between samples 
should therefore normalize for T. A low tumor cell fraction T will rescale all observed 
variant allele frequencies by a factor of T. For the computation of the heterogeneity index, 
we hence use the average VAF in sample j as an estimate of Tj and rescale all VAF values 
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by 1/Tj. To quantify and compare heterogeneity between cancers we calculated a continuous 
index of heterogeneity across all data from the targeted gene screen. This index measures the 
average discordance of mutation frequencies between any two pairs of samples, after 
adjusting for the extent of tumor cell content. The distance in tumor cell fraction adjusted 
VAF of gene i between sample j and k is computed as
Note that the above distance uses the distance to the CI if that appears closer to the observed 
VAF.
The heterogeneity index is then defined as the average distance between all genes and 
samples
where g is the number of genes and b the number of samples.
A heterogeneity value of 0 indicates perfect concordance of all samples and a value of 1 
would correspond to a situation, in which one sample has one additional fully clonal 
mutation. The heterogeneity index shows a strong inverse correlation with the branch time 
derived from whole-genome sequencing data in the sense that late-branching tumors display 
higher levels of geographic heterogeneity (rho=−0.73; Supplementary Fig. 3j).
(iv) Testing for heterogeneity—We used generalized linear models (glm’s) with an 
overdispersed binomial family to test whether the observed differences in variant allele 
frequencies between genes and samples in a given cancer can be explained by sampling 
fluctuations and differences in tumor cellularity alone. In a binomial glm the expected count 
of mutation i in sample j is given by
where f is the inverse logit function. Here αi sets the average frequency of each gene i and βj 
the common factor by which the gene frequencies change in sample j due to changes in 
tumor cellularity across samples. The parameter γij reflects the deviation of gene i in sample 
j from the trend imposed by the gene-specific allele frequency and cellularity in sample j. 
Note that there can be maximally (g-1) × (b − 1) γij’s because of the g+b shared factors αi 
and βj; the total number of observations is g × b.
An overall test for heterogeneity in a given cancer can then be conducted by testing whether 
all γij are zero, the alternative being that there is variation in any gene. This can be achieved 
by means of a likelihood ratio test (LRT) with (g-1) × (b − 1) degrees of freedom. We used 
the following R commands to derive a P-value for each sample: # x is a vector of variant 
allele counts for all lesions and biopsies; the length of x is g*b
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# n is a vector of the corresponding coverage
# genes is a factor() determining which gene x and n refer to
# biopsies is a factor() determining the biopsy
y <- cbind(x, n-x)
fit1 <- glm(y ~ genes + biopsies −1 + genes:biopsies, family=quasibinomial)
Ppatient <- anova(fit1, test=“LRT”, dispersion=1.5)[4,5]
P-values for each patient are subsequently corrected for multiple testing using the 
Benjamini-Hochberg procedure. P- and Q-values for each patient are reported in 
Supplementary Table 6. Similary we tested for variation in a particular gene i using an 
interaction term for this gene only:
fit.gene <- glm(y ~ genes + biopsies −1 + (genes==gene):biopsies, family=quasibinomial)
glm.p.value <- anova(fit.gene, test=“LRT”, dispersion=1.5)[4,5]
Additionally, we used glm’s with random effects, implemented in mgcv::gam(), to compute 
estimates of the variation of allele frequencies across samples. Gene-wise P-values from glm 
and gam models are also listed in Supplementary Table 6 (glm.p.value, gam.stddev, 
gam.p.value).
(v) Testing of clinical associations—Possible associations between clinical or 
pathological factors and genetic heterogeneity as a response are fitted using R’s lm() 
function. F-tests for overall association are then computed using the anova() command.
Basic principles of phylogenetic tree construction
For ten patients with multi-sample whole genome sequencing data, to model the subclonal 
structure we employed a number of bioinformatic and deductive reasoning approaches. The 
intellectual framework for our methods has been previously described1 and this approach 
has been extended and reinterpreted by many others since, using the original data51,52. All 
the conclusions we derive follow from three basic principles that also underlie the ‘mock’ 
trees derived from targeted capture data: (i) Cancer cells divide by asexual reproduction; (ii) 
The exact same mutation does not occur more than once during the evolution of the cancer 
(note that this so-called ‘infinitely many sites’ assumption is potentially not true for hot-spot 
mutations in, say, PIK3CA but will be true for virtually all passenger mutations given the 
size of the genome and the relative paucity of somatic mutations); (iii) Sequencing reads 
from massively parallel sequencing data are a random sample from the alleles present in the 
DNA.
The approach used in this paper followed 3 main steps: (i) Identification of large-scale 
subclonal copy number changes using the Battenberg algorithm as previously described1. 
Code is publically available at https://github.com/cancerit/cgpBattenberg; (ii) Clustering of 
subclonal somatic substitutions in whole genome data using a Bayesian Dirichlet process in 
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multiple dimensions across related samples as previously described47; (iii) Hierachical 
clustering across multiple samples by applying the ‘pigeon hole principle’ (PHP). Next, we 
performed validation of mutations in individual branches by targeted pulldown and 
validation of tree structures by independent clustering of indels and targeted pulldown 
substitutions following steps i–iii (Supplementary Fig. 1).
Each step is described in further detail below and for individual patients all potential 
solutions and reasoning are represented in Supplementary Figure 1, while individual cases 
are discussed in the Supplementary Note. Branch length, cluster sizes and poster confidence 
intervals are provided in Table 5.
(i) Whole genome data: mutation copy number and cancer cell fraction—For 
each mutation we calculated the mutation copy number as previously described27, using the 
mutant allele burden and the aberrant cell fraction and the locus specific copy number in the 
tumor and matched normal from ASCAT 32. The mutation copy number reflects the 
percentage of tumor cells within a sample carrying that mutation, and permits the cross-
comparison of the mutation in related samples despite differences in tumor purity and/ or 
copy number profiles as previously demonstrated47.
Mutations present on multiple copies of a chromosomal segment will have a mutation copy 
number greater than 1. To group mutations according to the percentage of cells containing it, 
the number of chromosomes carrying the mutation must be determined. For all mutations 
within amplified regions with a major allele copy number of C, the observed fraction of 
mutated reads is compared to the expected fraction of mutated reads resulting from a 
mutation present on 1,2,3,…C copies, assuming a binomial distribution. The fraction of 
cancer cells reporting the mutation, or ‘cancer cell fraction’, is then determined as the 
mutation copy number divided by the value of C with the maximum likelihood. Mutations 
are determined as clonal if reported by ~100% or tumor cells and subclonal if present in 
significantly less than 100% of cells.
For the purpose of comparing multiple related samples we excluded mutations from 
clustering analysis when they occur in a region of different copy number between samples 
and where the absence or altered copy number may explain the loss or different allele 
burden in the related samples. This approach is essential to reduce overestimation of inter-
sample heterogeneity. Large-scale losses, including those at the arm or whole chromosome 
level are frequent during evolution (Fig. 6b). Allelic loss can therefore be accompanied by 
loss of large numbers of point mutations and indels, which could be misinterpreted as gained 
events (i.e. ongoing evolution) in related samples. We placed the few individual driver 
mutations that occurred in regions of differential copy number state on the reconstructed tree 
post hoc. This then allowed them to be included in the temporal ordering inference.
(ii) Mutational clustering—For individual samples we inferred the number of subclones 
and the fraction of cells within each subclone using a previously described Bayesian 
Dirichlet process (DP) to cluster mutations according to their cancer cell fraction1,47. We 
extended this process into multiple dimensions for the 10 patients with multiple related 
samples where the number of mutant reads obtained from multiple related samples are 
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modeled as independent binomial distributions. Clusters are identified as local peaks in the 
posterior mutation density obtained from the DP. For each cluster, a region representing a 
‘basin of attraction’ is defined by a set of planes running through the point of minimum 
density between each pair of cluster positions. Mutations are assigned to the cluster in whose 
basin of attraction they are most likely to fall, using posterior probabilities from the DP. The 
R code required to sample clustering of mutations from a Dirichlet process and to make 
density plots of the clustering for each pair of samples is released as a supplementary 
material alongside this paper.
(iii) Hierarchical ordering of mutation clusters using the ‘Pigeon Hole 
Principle’—To determine the most likely phylogenetic tree we applied the PHP to 
determine the order in which mutational clusters arose in time and in relation to each other1. 
This principle operates upon the premise that if the fraction of cells reporting 2 different 
mutations adds up to >100%, then at least one tumor cell must contain both mutations. By 
the same principle one can determine if clusters of mutations are collinear i.e. on the same 
branch of the phylogenetic tree, and often the temporal order in which they arose. For all 
clonally related samples the same underlying phylogenetic tree must exist. This exerts a 
greater stringency to the inferred ordering of subclonal clusters – firstly the PHP must be 
fulfilled within all individual related samples and the ordering of events cannot be 
contradictory across related samples.
We attempted to reconstruct phylogenetic trees from the whole genome discovery 
substitution data using all clusters that are estimated to contain at least 150 substitutions or 
>=2% of all clustered substitutions. To reflect the lower overall numbers in validation and 
indel data this threshold requirement is set at 5%. In tree construction the percentage of all 
mutations in a cluster determined the relative branch length. Within an individual sample the 
cancer cell fraction fraction of a given cluster ‘X’, is the fraction of tumor cells reporting the 
mutations in cluster X. Credible intervals for the cancer cell fraction are typically small 
reflecting high numbers of mutations in most clusters. We allowed 5% variation in either 
direction to the assigned cluster sizes when determining ordering
In 7 out of 10 cases we derived a single, unambiguous phylogenetic tree solution from the 
whole genome discovery data (Supplementary Fig. 1). In two cases we identified one or 
more alternative tree using the discovery data (PD9773, PD9694) while in another case 
(PD9777), a soloution could only be deconvoluted using revised VAFs from high depth 
validation data. The validation clustering data identified additional tree branches in 2 cases 
(PD9775, PD9849). In cases where uncertainty as to the position or size of a branch the 
relevant branch(es) are ‘faded out’ in Fig. 4a. Our approaches are described in detail in the 
Supplementary Notes section where we focus on patient PD9694 and cases where solutions 
are less clear-cut.
Mutational signature analysis
Mutational signatures are detected in two independent ways: (i) de novo extraction based on 
somatic substitutions and their immediate sequence context and (ii) refitting of previously 
identified consensus signatures of mutational processes. We used a previously developed 
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theoretical model and its corresponding computational framework to perform de novo 
extraction53. Details of mutational signature analysis can be found in the Supplementary 
Note.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Study design
(a) Summary of samples within cohorts 1 and 2. n, number of subjects. (b) Geographical 
sampling approach: NW, northwest; NE, northeast; SW, southwest; SE, southeast within 
tumor hemisphere 1 and 2, plus 1 or 2 involved lymph nodes in 3 cases. For multifocal 
cancers all samples are taken from the single largest focus. (c) Source of retrospective 
clinical samples in relation to primary tumor management. RD, residual disease; NAC, Neo-
adjuvant chemotherapy; pCR, pathological complete response.
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Figure 2. Systematic sampling reveals spatial and temporal tumor evolution
(a–d) Somatic mutation genotypes, presented as coxcomb plots, overlaid on the sample 
schema described in Figure 1b. Point estimates of the variant allele fraction (VAF) or copy 
number (LogR) is represented by the lateral extension of the outlined wedge. Pale wedges 
lacking an outline represent the 95% confidence interval – if coverage is low the confidence 
of the VAF is reduced and the pale wedge appears beyond the point estimate. ER, Estrogen 
receptor; PgR, Progesterone receptor; IDCA, invasive ductal carcinoma. Driver mutations 
and arm level copy number gains (+) and losses (−) detected in each cancer are annotated in 
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the case-specific mutation legend. Significant heterogeneity amongst point mutations in 
individual cancers is determined using generalized linear models (glm) and Benjamini-
Hochberg correction: *, q < 0.05 indicates significant point mutational heterogeneity; **, 
non-significance. (a) No detected intra-tumoral heterogeneity (q=0.8). (b–c) Local 
expansion of subclones (red arrow heads). (d) Complex intermixing of subclones: Individual 
mutations (each highlighted with a different colored arrowhead) appear in different 
combinations of samples. Mock phylogenetic trees are also shown: The presence and 
absence of mutations across related samples indicate distinct subclones and dictate the 
branching structure, the number of mutations in each subclone determine branch lengths. 
See ftp://ftp.sanger.ac.uk/pub/cancer/YatesEtAl/ for coxcomb and heatmap plots for every 
cancer in the cohort.
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Figure 3. Subclonal patterns in multifocal breast cancers
(a–c,e) Targeted capture genomic analysis of subclonal structure in four subjects’ multifocal 
cancers. Coxcomb plots and mock phylogenetic trees are generated as described in Figure 2. 
Plots from multiple samples from the same tumor focus are grouped together within grey 
outlined boxes. Colored arrow-heads identify subclones that are shared by fewer than all 
invasive foci. (a) Case PD14753: Genotypes of 5 samples from 3 disease foci indicate deep 
branching of the tree, driver heterogeneity and subclone intermingling across foci. (b) Case 
PD9193: Genotypes of 7 samples from 4 disease foci demonstrate subclone intermingling. 
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Orientation within mastectomy specimen: UIQ = Upper Inner Quadrant, UOQ = Upper 
Outer quadrant, LIQ = Lower Inner Quadrant, LOQ = Lower Outer Quadrant. (c) Case 
PD9694: Parallel evolution with 2 unique PTEN driver mutations in different foci. 
Schematic representation of pathological features in the mastectomy specimen. Dashed line 
represents the deep (chest wall) margin. Scale represents 3mm in a formalin fixed paraffin 
embedded tissue section. (d) Case PD9694: PTEN immunohistochemistry shows PTEN 
protein to be present in DCIS but lost in invasive disease foci 1 and 2. Scale = 100 microns. 
(e) Genotypes of 3 samples from 2 disease foci in PD9770, prior to chemotherapy and 2 
samples from Focus 1 after neoadjuvant chemotherapy. Focus 2 exhibited a pathological 
complete response to 3 cycles of each chemotherapy agent.
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Figure 4. The genome-wide spectrum of branching evolution
(a) Phylogenetic trees generated by clustering genome-wide point mutation data from 10 
multiregion sampled primary cancers. Relative branch lengths are determined from the 
proportion of mutations in each branch. An ‘x’ indicates the most recent common ancestor 
inferred from treatment-naive samples alone. (a and c) Cases where post-treatment samples 
are available (green highlighting bar above trees): Red node(s) indicate where subclones 
only detected after treatment (branches with red outlines) emerged within the tree. Branches 
only detected amongst pre-treatment samples are indicated by a purple outline, black 
branches indicate detection in both pre- and post-chemotherapy samples. Likely driver genes 
are colored according to mutation type: amplification (red text), homozygous deletion (blue 
text), point mutation (black text) and potentially relevant structural variants (purple text). 
Cancer type is specified: triple negative = TN, DCIS = ductal carcinoma in situ. Type of 
neo-adjuvant chemotherapy (NAC): Epi, Epirubicin; T, Docetaxel; P, Paclitaxel; (F)EC, 
(Fluorouracil), Epirubicin, Cyclophosphamide (b) The subclonal composition of individual 
samples where colors correspond to the tree branch in (a) and the area is proportional to the 
percentage of cells in that sample that contain the mutations in that branch. (c) Mock trees 
inferred from targeted capture data for samples with pre- and post-treatment samples. Six 
samples with no branching are not presented. Branches are colored as stated above for 
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genome data. (d) Pearson’s correlation for heterogeneity estimates from whole genome and 
targeted capture data.
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Figure 5. Subclonal driver mutations and parallel evolution
(a) Heatmap of somatic driver mutations and copy number changes identified from genomic 
sequencing of 50 tumors. Single base substitutions and small insertions and deletions are 
reported by red squares, intense red when detected in all associated samples from the tumor 
(omnipresent), pink when present in less than all samples, or clearly subclonal. Omnipresent 
and heterogeneous copy number changes are reported by dark-blue and light-blue squares 
respectively. (b–d) Three examples of parallel evolution, see fourth example in Figure 3c–d 
and 4a (PD9694). (c) One possible phylogenetic tree and sample subclonal compositions 
inferred from targeted capture data (as described in Fig. 2 and 4c legends) with TP53 
mutations arising on 3 branches. See also Supplementary Figure 3 (PD9850). (b) Multiple 
independent episomal amplification events in FGFR2 and (d) two independent deletions in 
RUNX1 detected in 2 samples from the same cancer. In copy number graphs (b and d) the 
black dots reflect the number of copies of genomic DNA from that specific locus, with a 
level greater than 2 reflecting a net gain and a value less than 2 reflecting a loss. 
Reconstructed rearrangement breakpoints are represented by colored lines according to 
whether they are detectable in pre (purple) or post (red) chemotherapy samples only. The 
type of event is indicated by the position of the arc joining the breakpoints: D, deletion; TD, 
tandem duplication.
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Figure 6. Structural variants shape cancer evolution
(a) Comparison of the proportion of substitutions (subs) and structural variants (SVs) that 
are subclonal in each cancer. Inset graph shows scatterplot and Pearson’s correlation 
coefficient (r). (b) Clonal and subclonal complex rearrangements (as described in the 
Supplementary Note section) and arm level loss of heterozygosity (LOH) events. The 
average genome-wide ploidy is indicated: T = tetraploid (4 copies), D = diploid (2 copies). 
(c) Breakdown of clonal and subclonal structural variants by category (inversion = Inv, 
deletion = Del, inter-chromosomal translocation = Trans, tandem duplication = TD). For 
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each cancer the total number of mutations assigned to the trunk (T) or branches (B) is 
indicated in the top left corner, while the proportion of each mutation type that is subclonal 
(i.e. within the branches) is added as a percentage above each bar. (d) Case PD9770: 
Examples of two subclonal, complex structural rearrangements arising on separate branches 
of the phylogenetic tree. In PD9770c structural rearrangements link multiple regions of 
amplification across 3 chromosomes. Amplifications include multiple genomic regions that 
have been previously identified as recurrently amplified in cancers and are represented by 
red arrows while the locations of known oncogenes are marked by pink bars. In PD9770d 
these events are not seen but a breakage fusion-bridge event amplifies segments including 
the CDC7 gene. Rearrangement types include: Interchromosomal translocations (Tr), tail-to-
tail inversions = TT (green), head-to-head inversions = HH (orange), tandem duplication = 
TD (orange), deletions = D (purple)
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